Literature DB >> 2671141

Third generation cephalosporins.

G R Donowitz1.   

Abstract

The third generation cephalosporins demonstrate greater potency, broader antibacterial spectrum, and more favorable pharmacologic characteristics than other cephalosporins. The majority of strains of E. coli, Klebsiella pneumoniae, and Proteus are susceptible, including strains resistant to aminoglycosides, anti-Pseudomonas penicillins, and other cephalosporins. Pseudomonas aeruginosa is susceptible to a subgroup of third generation agents including ceftazidime, cefoperazone, and the experimental agents cefpirome and cefpiramide. Penetration into the cerebrospinal fluid is excellent especially for cefotaxime, ceftazidime, ceftriaxone, and ceftizoxime. These agents are safe, sharing most of the known toxicities of other beta-lactam compounds. Their greatest use is in the therapy of difficult to treat gram-negative bacterial infections, including meningitis, nosocomial infections, and infections caused by Pseudomonas aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2671141

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  5 in total

1.  Review of the pharmacology, pharmacokinetics, and clinical use of cephalosporins.

Authors:  D Kalman; S L Barriere
Journal:  Tex Heart Inst J       Date:  1990

2.  Identification and Characterization of Cefazolin-Induced Liver Injury.

Authors:  Saleh A Alqahtani; David E Kleiner; Marwan Ghabril; Jiezhun Gu; Jay H Hoofnagle; Don C Rockey
Journal:  Clin Gastroenterol Hepatol       Date:  2014-12-18       Impact factor: 11.382

3.  Randomized trial comparing ceftriaxone with cefonicid for treatment of spontaneous bacterial peritonitis in cirrhotic patients.

Authors:  J Gómez-Jiménez; E Ribera; I Gasser; M A Artaza; O Del Valle; A Pahissa; J M Martínez-Vázquez
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

4.  Antimicrobial pharmacokinetics in endophthalmitis treatment: studies of ceftazidime.

Authors:  T A Meredith
Journal:  Trans Am Ophthalmol Soc       Date:  1993

5.  Cefepime : The Last Generation or the First Enhanced-Potency Broad Spectrum Cephalosporin?

Authors:  C C Sanders; E S Moland
Journal:  Clin Drug Investig       Date:  1995-12       Impact factor: 2.859

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.